Trialbee, a patient matching and enrolment platform, and uMotif, a patient-centric data capture provider, are partnering hoping to improve the patient experience and improve trial accessibility globally. The companies’ integrated platforms simplify trial activities from initial awareness through enrollment and data collection during study conduct and close-out.
Patients are digitally matched to study protocols via Trialbee HIVE. Qualified, study-ready patients are then consented at-site or remotely through the Trialbee platform, which is integrated with uMotif’s application. Once enrolled, patients use the engaging uMotif app to capture large volumes of ePRO, eDiary and symptom data in real-time throughout the duration of a trial. Patients are empowered to manage and collect their data in an application, while sponsors receive an understanding of patient symptoms and behavior.
For more information, click here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.